LAUSR

Cancer Mutations that cause activation of the KRAS oncogene are common in human cancer, including treatment-resistant tumor types such as lung and pancreatic cancer. KRAS is notoriously difficult to target with small molecules. To overcome this issue, Ross et al. turned to genetic technology to develop an antisense oligonucleotide–based therapy for inhibiting KRAS. The antisense oligonucleotide was chemically modified to allow systemic delivery through subcutaneous injection, avoiding the need for a specialized delivery vehicle. The authors tested the efficacy of this therapy in multiple mouse models of non–small cell lung cancer and evaluated its safety in primates, demonstrating its potential suitability for translation to humans. Sci. Transl. Med. 9 , eaal5253 (2017).